Home› Library› Protocol› Ly3437943
LY3437943 reconstitution protocol
Reconstitution and storage parameters for LY3437943, the triple GIP/GLP-1/glucagon receptor agonist. Reference values from published Phase 2 handling protocols.
RECONSTITUTION & RESEARCH PROTOCOLS
Emerging clinical evidenceResearch protocol intensities, summarized from published literature. The math is computed for the vial size you pick. Not a dosing recommendation.
Phase 2 TRIPLE-1 trial published in NEJM 2023. Phase 3 (TRIUMPH) ongoing.
Reference research protocols from published peer-reviewed studies. Each card cites its source. This calculator is not a dosing recommendation. For research use only. Selection of any specific protocol is the responsibility of the qualified investigator under appropriate institutional oversight.
This protocol describes the reconstitution and storage of lyophilized LY3437943 in standard research workflows. LY3437943 is a triple GIP/GLP-1/glucagon receptor agonist studied in Phase 2 research for incretin pharmacology and energy balance. Values below are derived from published handling literature; experimental design parameters are the responsibility of the qualified investigator.
At a glance
| Parameter | Value |
|---|---|
| Recommended diluent | Bacteriostatic Water (USP, 0.9% benzyl alcohol) |
| Recommended volume (10 mg vial) | 2.0 mL |
| Final concentration | 5 mg/mL |
| Stability — lyophilized | ≥24 months at -20 °C, light-protected, sealed |
| Stability — reconstituted | 30 days at 2–8 °C in original vial |
| Freeze-thaw | Avoid on reconstituted solution. Aliquot if longer-term storage needed. |
Procedure
- Equilibrate. Allow the sealed vial to come to room temperature before reconstitution.
- Sterile prep. Wipe the stopper with isopropyl alcohol and allow to dry. Use a sterile syringe with a 21G or larger needle.
- Inject diluent slowly. Direct the stream along the inner glass wall — not directly onto the lyophilized cake.
- Dissolve gently. Swirl in a slow rotational motion. Do not shake. The cake should dissolve within 30–60 seconds.
- Verify. Solution should be clear and colorless. If cloudy or discolored, do not use — contact Merit (info@meritpeptides.com).
Compound notes
LY3437943 is a 39-amino-acid peptide engineered to activate all three incretin receptors. Like tirzepatide it has a fatty-acid modification that extends half-life into the once-weekly range (~6 days reported in human PK studies). The molecule is more sensitive to repeated freeze-thaw than tirzepatide due to its higher molecular weight (~5,419 Da) and greater conformational complexity — aliquot the moment you reconstitute if extended storage is planned.
Storage
Reconstituted LY3437943 is stable for approximately 30 days at 2–8 °C in the original vial. Beyond that, aliquot into sterile single-use tubes and freeze at -20 °C or -80 °C. Avoid freeze-thaw on the reconstituted form. Lyophilized stability is at least 24 months at -20 °C light-protected.
Notes
This protocol describes reconstitution parameters used in published peptide-handling literature. It is not a recommendation for any particular study design. Selection of concentration, interval, and route is the responsibility of the qualified investigator under appropriate institutional oversight. For research use only. Not for human consumption.
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist LY3437943 for Obesity — a Phase 2 Trial. NEJM 2023;389:514–526. PMID: 37366315
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metab 2022;34:1234–1247. PMID: 35985288
Was this helpful?
We reply to every research inquiry.